BRPI0822002A2 - tratamento de doenças de cólon ou prevenção de carcinoma colorretal com derivados de imidazoquinolina. - Google Patents

tratamento de doenças de cólon ou prevenção de carcinoma colorretal com derivados de imidazoquinolina.

Info

Publication number
BRPI0822002A2
BRPI0822002A2 BRPI0822002A BRPI0822002A BRPI0822002A2 BR PI0822002 A2 BRPI0822002 A2 BR PI0822002A2 BR PI0822002 A BRPI0822002 A BR PI0822002A BR PI0822002 A BRPI0822002 A BR PI0822002A BR PI0822002 A2 BRPI0822002 A2 BR PI0822002A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
colorectal carcinoma
colon disease
imidazoquinoline derivatives
Prior art date
Application number
BRPI0822002A
Other languages
English (en)
Portuguese (pt)
Inventor
Istvan Szelenyi
Joachim Maus
Ursula Petzold
Original Assignee
Meda Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40419193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0822002(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Meda Ab filed Critical Meda Ab
Publication of BRPI0822002A2 publication Critical patent/BRPI0822002A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
BRPI0822002A 2008-01-15 2008-12-23 tratamento de doenças de cólon ou prevenção de carcinoma colorretal com derivados de imidazoquinolina. BRPI0822002A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US645908P 2008-01-15 2008-01-15
PCT/EP2008/011088 WO2009089900A1 (en) 2008-01-15 2008-12-23 Treatment of colon diseases or prevention of colorectal carcinoma with imidazoquinoline derivatives

Publications (1)

Publication Number Publication Date
BRPI0822002A2 true BRPI0822002A2 (pt) 2015-10-13

Family

ID=40419193

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0822002A BRPI0822002A2 (pt) 2008-01-15 2008-12-23 tratamento de doenças de cólon ou prevenção de carcinoma colorretal com derivados de imidazoquinolina.

Country Status (15)

Country Link
US (1) US8008319B2 (enExample)
EP (1) EP2237780A1 (enExample)
JP (1) JP2011509956A (enExample)
CN (1) CN101909624A (enExample)
AU (1) AU2008347400B2 (enExample)
BR (1) BRPI0822002A2 (enExample)
CA (1) CA2708559C (enExample)
EA (1) EA018579B1 (enExample)
GE (1) GEP20125605B (enExample)
IL (1) IL205819A (enExample)
MX (1) MX2010007699A (enExample)
NZ (1) NZ586161A (enExample)
UA (1) UA101339C2 (enExample)
WO (1) WO2009089900A1 (enExample)
ZA (1) ZA201003906B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2491035T1 (sl) 2009-10-22 2017-10-30 Gilead Sciences, Inc. Derivati purina ali deazapurina uporabni za zdravljenje (med drugimi) virusnih okužb
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
SG11201605296SA (en) 2014-01-10 2016-07-28 Birdie Biopharmaceuticals Inc Compounds and compositions for treating her2 positive tumors
DK3166976T3 (da) 2014-07-09 2022-04-11 Birdie Biopharmaceuticals Inc Anti-pd-l1-kombinationer til behandling af tumorer
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN106943598A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-her2组合
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
US11517567B2 (en) * 2017-06-23 2022-12-06 Birdie Biopharmaceuticals, Inc. Pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2078547C1 (ru) * 1995-11-28 1997-05-10 Центральный научно-исследовательский рентгено-радиологический институт МЗМП РФ Способ лечения полипоза желудка и двенадцатиперстной кишки
UA75622C2 (en) * 2000-12-08 2006-05-15 3M Innovative Properties Co Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
EP1351678A2 (en) * 2001-01-02 2003-10-15 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
US20060193789A1 (en) * 2002-10-25 2006-08-31 Foamix Ltd. Film forming foamable composition
ATE400573T1 (de) * 2003-11-21 2008-07-15 Novartis Pharma Gmbh 1h-imidazochinolinderivate als proteinkinaseinhibitoren

Also Published As

Publication number Publication date
AU2008347400B2 (en) 2014-12-11
US8008319B2 (en) 2011-08-30
US20090182005A1 (en) 2009-07-16
CA2708559C (en) 2015-10-06
CA2708559A1 (en) 2009-07-23
IL205819A0 (en) 2010-11-30
MX2010007699A (es) 2010-08-04
NZ586161A (en) 2012-05-25
IL205819A (en) 2013-02-28
GEP20125605B (en) 2012-08-10
WO2009089900A1 (en) 2009-07-23
ZA201003906B (en) 2011-03-30
EA201001164A1 (ru) 2010-12-30
EA018579B1 (ru) 2013-09-30
JP2011509956A (ja) 2011-03-31
AU2008347400A1 (en) 2009-07-23
EP2237780A1 (en) 2010-10-13
UA101339C2 (ru) 2013-03-25
CN101909624A (zh) 2010-12-08

Similar Documents

Publication Publication Date Title
BRPI0822002A2 (pt) tratamento de doenças de cólon ou prevenção de carcinoma colorretal com derivados de imidazoquinolina.
BRPI0814889A2 (pt) tratamento com ligantes alfa7-seletivos.
BR112012002124A2 (pt) tratamento da doença de crohn com laquinimode.
BRPI0912683A2 (pt) tratamento de tumores metastáticos
BRPI0920104A2 (pt) tratamento de soluções ou de águas residuais
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
FR2921499B1 (fr) Structure orientable de type catheter ou endoscope
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
BRPI0906436A2 (pt) Derivados de ftalazinona
FR2932478B1 (fr) Composes utiles pour le traitement des cancers.
HUE043326T2 (hu) Akut limfoblasztos leukémia kezelése
BRPI0917321A2 (pt) prevenção, tratamento e diagnóstico de infecção por p. gingivalis
EP2310526A4 (en) COMPOSITIONS FOR THE DETECTION AND TREATMENT OF COLORECTAL CANCER
BRPI0814624A2 (pt) Tratamento de doença neurodegenerativa progresiva com ibudilaste
NO345064B1 (no) Anvendelse av kombinasjonslegemidler, omfattende antimykotika
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
BRPI1016117A8 (pt) derivados de isoxazol-isoxazol e isoxazol-isotiazol.
BRPI0813364A2 (pt) Métodos de diagnóstico e tratamento de câncer.
BRPI1008517A2 (pt) direcionamento duplo de mir-208 e mir-499 no tratamento de doenças cardíacas.
SI2229369T1 (sl) Derivati 6,7-dialkoksi kinazolina, uporabni za zdravljenje motenj, povezanih z rakom
BRPI0718850A2 (pt) Métodos de tratar, diagnosticar ou detectar câncer
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
DK2081950T3 (da) Med irinotecanbehandling forbundne ekspressionsprofiler
IL216369B (en) Alpha-difluoromethylornithine for carcinoma diagnosis and treatment of patients with odc1 genotype
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]